CN Patent

CN101123878A — 氨基酸前药

Assigned to Signature R&D Holdings LLC · Expires 2008-02-13 · 18y expired

What this patent protects

本发明涉及一种前药，其包括连接到药剂或药物的氨基酸，所述药剂或药物上具有羟基、氨基、羧基或其酰化衍生物。所述前药可与制备前药的药物一样使用，但治疗性能增强了。事实上，本发明的前药增强了至少两个治疗性能，如所定义的。本发明还涉及含有前药的药物组合物。

USPTO Abstract

本发明涉及一种前药，其包括连接到药剂或药物的氨基酸，所述药剂或药物上具有羟基、氨基、羧基或其酰化衍生物。所述前药可与制备前药的药物一样使用，但治疗性能增强了。事实上，本发明的前药增强了至少两个治疗性能，如所定义的。本发明还涉及含有前药的药物组合物。

Drugs covered by this patent

Abilify (aripiprazole) · Generic (originally Otsuka/BMS)

Patent Metadata

Patent number: CN101123878A
Jurisdiction: CN
Classification: —
Expires: 2008-02-13
Drug substance claim: No
Drug product claim: No
Assignee: Signature R&D Holdings LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.